XTX Topco’s Iovance Biotherapeutics IOVA Stock Holding History

XTX Topco’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-107,480	Closed	-$377K	–	4414
2026 Q1	$377K	Sell	107,480 -415,454	-79%	-$1.33M	0.01%	2281
2025 Q4	$1.43M	Buy	522,934 +312,413	+148%	+$723K	0.04%	777
2025 Q3	$457K	Buy	210,521 +170,385	+425%	+$402K	0.02%	1142
2025 Q2	$69K	Sell	40,136 -141,696	-78%	-$353K	﹤0.01%	1957
2025 Q1	$606K	Buy	+181,832	New	+$938K	0.03%	885
2023 Q4	–	Sell	-18,863	Closed	-$85.8K	–	1832
2023 Q3	$85.8K	Buy	+18,863	New	+$123K	0.01%	1203
2023 Q1	–	Sell	-41,170	Closed	-$263K	–	1466
2022 Q4	$263K	Buy	41,170 +23,092	+128%	+$180K	0.06%	680
2022 Q3	$173K	Buy	+18,078	New	+$208K	0.04%	828
2021 Q4	–	Sell	-8,419	Closed	-$208K	–	836
2021 Q3	$208K	Buy	+8,419	New	+$198K	0.07%	485

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

XTX Topco's IOVA Position: Q2 2026 in Review

XTX Topco sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 107,480 shares — an estimated $377K sold.

XTX Topco first reported a position in IOVA in Q3 2021 and held it in 9 quarters. The position peaked at $1.43M in Q4 2025. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

XTX Topco reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 107,480 Iovance Biotherapeutics shares in Q2 2026, an estimated $377K.
XTX Topco first reported a position in Iovance Biotherapeutics in Q3 2021 and held it in 9 quarters.
XTX Topco's Iovance Biotherapeutics position peaked at $1.43M in Q4 2025.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.